Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

NCT03268954 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

454

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndrome
Leukemia, Myelomonocytic, Chronic
Leukemia, Myeloid, Acute

Interventions

DRUG: Azacitidine
DRUG: Pevonedistat

Sponsor

Takeda

Collaborators

[object Object]